For chemotherapy agents that vaporize (e.g., Carmustine, Cyclophosphamide, Doxorubicin, Fluorouracil), has anyone completed a hazard/risk assessment of exposure once they have been further diluted for administration? Specifically, do you handle a spill of a diluted preparation the same as you would (e.g, require PAPR), if undiluted liquid was spilled?
Kind regards,
Ronda Whipple PharmD